natgillin/translations-raw huggingface dataset:
Euro-Labor SA, Rua Alfredo da Silva no16, 2610-016 Amadora, Portugal 
Euro-Labor SA, Rua Alfredo da Silva no16, 2610-016 Amadora, Portugalska
Lornoxicam has no effect on vital signs (e.g. body temperature, respiratory rate, heart rate, blood pressure, ECG, spirometry). 
Lornoksikam ne vpliva na vitalne znake (npr. telesno temperaturo, hitrost dihanja, krvni tlak, EKG, spirometrijo).
Another three cases were caused by cardiovascular events and occurred in patients with rheumatological disorders participating in long-term studies. 
Drugi trije smrtni primeri so nastali zaradi kardiovaskularnih dogodkov in sicer pri bolnikih z revmatološkimi motnjami, ki so sodelovali v dolgoročnih raziskavah.
Maximum plasma concentrations are achieved after approximately 30 minutes. 
Najvišje plazemske koncentracije doseže po približno 30 minutah.
BATCH NUMBER 
ŠTEVILKA SERIJE Batch
Treatment with lornoxicam should be discontinued if renal function deteriorates during treatment. 
Zdravljenje z lornoksikamom morate prekiniti, če se med zdravljenjem delovanje ledvic poslabša.
The MAH has applied the PhVWP core information for NSAIDs in relation to gastrointestinal safety, skin reactions and cardiovascular safety (October 2005). 
Imetnik dovoljenja za promet je uporabil osrednje informacije za NSAID, ki jih je priskrbela delovna skupina PhVWP, v zvezi z gastrointestinalno varnostjo, kožnimi reakcijami in kardiovaskularno varnostjo (oktober 2005).
For all the pharmaceutical forms and strengths of lornoxicam It was agreed that the following would be included: - Methotrexate: Increased serum concentration of methotrexate. 
Za vse farmacevtske oblike in jakosti lornoksikama Dogovorjeno je bilo, da se vključi naslednje: - Metotreksat: Povečana koncentracija metotreksata v serumu.
Nycomed Austria GmbH, St. Peter Strasse 25, 4020 Linz, Austria 
Nycomed Austria GmbH, St. Peter Strasse 25, 4020 Linz, Avstrija
Only 2/7 studies included a 16 mg dose and only 1/7 study included a 32 mg dose. 
Samo 2 od 7 raziskav sta vključevali 16 mg odmerek in samo ena od 7 raziskav je vključevala 32 mg odmerek.
Concomitant intake of food may reduce the uptake of the medicinal product. 
Sočasno uživanje hrane lahko zmanjša privzem zdravila.
Uncommon: Increase in liver function tests, SGPT (ALT) or SGOT (AST). 
Občasni: zvišane ravni v preiskavah jetrne funkcije, SGPT (ALT) ali SGOT (AST).
After IM injection, maximum plasma concentrations are achieved after approximately 0.4 hours. 
injiciranju doseže najvišje plazemske koncentracije po približno 0,4 ure.
Metabolic/Endocrine 
Presnovni/endokrini
If visible signs of deterioration are seen in the medicinal product, the product must be disposed of in accordance with local requirements 
Če ima zdravilo vidne znake kvarjenja, ga zavrzite v skladu z lokalnimi predpisi.
When tested in animal models, lornoxicam did not induce liver enzymes. 
V poskusih na živalskih modelih lornoksikam ni induciral jetrnih encimov.
The analgesic properties of lornoxicam have been demonstrated successfully in several clinical trials during development of the drug. 
Analgetične lastnosti lornoksikama so uspešno dokazali v več kliničnih preskušanjih v fazah razvoja zdravila.
The aim of the overall analysis (meta-analysis) was to compare the efficacy of different dosages of lornoxicam with comparator drugs or placebo, in a cohort of RA patients. 
Cilj celokupne analize (metaanalize) je bila primerjava učinkovitosti različnih odmerkov lornoksikama s primerjalnimi zdravili ali placebom v skupini bolnikov z RA.
- Beta-adrenergic blockers: Decreased antihypertensive efficacy. 
- Zaviralci beta-adrenergičnih receptorjev: Zmanjšana antihipertenzivna učinkovitost.
The absolute bioavailability (calculated on AUC) after IM administration is 97 % 
Absolutna biološka razpoložljivost (izračunana na osnovi AUC) po i.m.
Lornoxicam is metabolised completely, and approximately 2/3 is eliminated via the liver and 1/3 via the kidneys as inactive substance. 
Lornoksikam se popolnoma presnovi: približno 2/3 se ga izloči preko jeter, 1/3 pa preko ledvic v obliki neaktivne snovi.
Treatment of rheumatoid arthritis has been approved by 16/16 Member States (AT, BE, CZ, DE, DK, EE, ES, GR, HU, IT, LT, LV, PT, SE, UK). 
Zdravljenje revmatoidnega artritisa je odobrilo 16 od 16 držav članic (AT, BE, CZ, DE, DK, EE, ES, GR, HU, IT, LT, LV, PT, SE, UK).
- Digoxin: Decreased renal clearance of digoxin. 
- Digoksin: Zmanjšan ledvični očistek digoksina.
The classic rheumatology disorders were investigated in 26 studies with 3,621 patients: 12 studies in rheumatoid arthritis (RA), 8 studies in osteoarthritis (OA), 3 in both indications and 3 in other rheumatology indications (i.e. ankylosing spondylitis (AKS), non-arthritic rheumatism and acute gout). 
Klasične revmatološke bolezni so preučevali v 26 raziskavah s 3621 bolniki: 12 raziskavah revmatoidnega artritisa (RA), 8 raziskavah osteoartritisa (OA), 3 v obeh indikacijah in 3 v drugih revmatoloških indikacijah (npr. ankilozni spondilitis (AKS), neartritični revmatizem in akutni urični artritis).
After oral administration about 50% is excreted in the faeces and 42% through the kidneys, mainly as 5-hydroxylornoxicam. 
Pri peroralnem dajanju se približno 50 % odmerka izloči v blatu in 42 % preko ledvic, v glavnem kot 5-hidroksilornoksikam.
Nycomed Pharma GmbH, Edisonstrasse 16, 85716 Unterschleissheim, Germany 
Nycomed Pharma GmbH, Edisonstrasse 16, 85716 Unterschleissheim, Nemčija
4 of 7 studies investigated the efficacy in third molar surgery pain (and three of these studies were already included in meta-analysis 
V 4 od 7 raziskav je bila preučevana učinkovitost glede bolečine pri operativni odstranitvi modrostnih zob (tri od teh raziskav so bile že vključene v 1. metaanalizo).
Treatment of osteoarthritis has been approved by 14/16 Member States (AT, BE, CZ, DE, DK, ES, GR, HU, LT, LV, PT, SE, UK). 
Zdravljenje osteoartritisa je odobrilo 14 od 16 držav članic (AT, BE, CZ, DE, DK, ES, GR, HU, LT, LV, PT, SE, UK).
Powder: Yellow, solid substance 
Prašek: rumena trdna snov
Lornoxicam is found in the plasma in unchanged form and as its hydroxylated metabolite. 
Lornoksikam se nahaja v plazmi v nespremenjeni obliki ter kot hidroksiliran presnovek.
The duration of blinded treatment was 4 weeks for studies CT18 and CT80 and 12 weeks for CT33 and CT63. 
Slepo zdravljenje je pri raziskavah CT18 in CT80 trajalo 4 tedne, pri raziskavah CT33 in CT63 pa 12 tednov.
Very rare: Hepatocellular damage. 
Zelo redki: hepatocelične poškodbe.
Data from 103 clinical studies were included in the SDB including 57 double-blind studies, 4 singleblind studies and 50 open studies of which 8 were follow-up to randomised studies. 
V zbirko podatkov o varnosti so bili vključeni podatki iz 103 kliničnih raziskav, vključno s 57 dvojno slepimi raziskavami, 4 enojno slepimi raziskavami in 50 odprtimi raziskavami, od katerih jih je bilo 8 nadaljevanje randomiziranih raziskav.
Thus meta-analysis 3 does not essentially contribute to the MAH's claim for an unrestricted use of lornoxicam in the treatment of pain. 
Zato 3. metaanaliza ne prispeva bistveno k zahtevi imetnika dovoljenja za promet za neomejeno uporabo lornoksikama pri zdravljenju bolečin.
It increased by duration of treatment (0.3%, 0.5% and 1.9% for short-, medium- and long-term treatment, respectively) and was influenced by the vulnerability of patients with chronic diseases in long-term treatment: The majority of patients with SADR had RA or were elderly patients included in post-operative pain studies such as hip replacement. 
Povečevala se je s trajanjem zdravljenja (0,3 % pri kratkoročnem zdravljenju, 0,5 % pri srednjeročnem zdravljenju in 1,9 % pri dolgoročnem zdravljenju); nanjo je vplivala občutljivost bolnikov s kroničnimi boleznimi pri dolgoročnem zdravljenju: Večina bolnikov z resnimi neželenimi učinki je imela RA oz. so bili starejši bolniki, ki so bili vključeni v postoperativne raziskave bolečin, npr. po zamenjavi kolka.
Rare: Dermatitis, purpura. 
Redki: dermatitis, pupura.
Pregnancy and lactation - Section 4.6 
Nosečnost in dojenje - poglavje 4.6
More than 12,000 patients were included in the 103 studies of which 43 were classified as phase I with 810 patients. 
V 103 raziskavah, od katerih jih je bilo 43 uvrščenih med raziskave I. faze z 810 bolniki, je sodelovalo več kot 12.000 bolnikov.
Gastrointestinal disorders can for example be treated with a prostaglandin analogue or ranitidine. 
Prebavne težave lahko na primer zdravimo s prostaglandinskim analogom ali ranitidinom.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption should not take this medicine. 
Bolniki z redko dedno intoleranco galaktoze, pomanjkljivostjo laktaze Lapp ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
The absolute bioavailability of Xefo Rapid film-coated tablets is 90-100 % which is equivalent to Xefo film-coated tablet. 
Absolutna biološka razpoložljivost zdravila Xefo Rapid filmsko obložene tablete je 90-100 %, kar je enakovredno absolutni biološki razpoložljivosti zdravila Xefo filmsko obložene tablete.
Compatibilities 
Združljivosti
CYP2C9 is involved in this biotransformation of lornoxicam. 
V tem postopku biotransformacije lornoksikama sodeluje CYP2C9.
The submitted efficacy data on pain focus on meta-analyses from 12 placebo-controlled pain studies (including partly also active controls) [See Table below]. 
Predloženi podatki o učinkovitosti glede bolečin so osredotočeni na metaanalizo 12 raziskav bolečin, kontroliranih s placebom (delno so vključene tudi primerjalne učinkovine) [Glejte spodnjo tabelo].
PHARMACEUTICAL FORM AND CONTENTS 250 film-coated tablets 
FARMACEVTSKA OBLIKA IN VSEBINA 250 filmsko obloženih tablet
The most commonly observed adverse events of NSAIDs are gastrointestinal in nature. 
Najpogosteje opaženi neželeni učinki NSAID so gastrointestinalne narave.
Therefore serum lithium levels require monitoring, especially during initiation, adjustment and withdrawal of treatment. 
Spremljanje koncentracije litija v serumu je zato potrebno, še zlasti med začetkom, ob prilagoditvi in prenehanju zdravljenja.
The divergences between the MS in the wording of the description of the pharmacokinetic properties have been harmonised. 
Razhajanja med državami članicami pri besedilu opisa farmakokinetičnih lastnosti so bila usklajena.
Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation after use of a prostaglandin synthesis inhibitor in early pregnancy. 
Podatki iz epidemioloških študij kažejo zvišano tveganje splava in srčnih okvar po uporabi zaviralca sinteze prostaglandinov v zgodnji nosečnosti.
The mean elimination half-life is 3-4 hours. 
Povprečna razpolovna doba eliminacije je približno 3-4 ure.
Lornoxicam is excreted in milk of lactating rats in relatively high concentrations. 
Pri podganah v obdobju laktacije se lornoksikam izloča v mleku v relativno visokih koncentracijah.
For several drugs causing interaction and which possibly increase the risk of toxicity in combination with NSAIDs/lornoxicam, the recommendation regarding drug monitoring (for methotrexate, lithium and cyclosporine) has been included in the SPC. 
Za nekatera zdravila, ki povzročajo medsebojno delovanje in ki utegnejo v kombinaciji z NSAID/lornoksikamom povečati tveganje za toksičnost, je v SPC priloženo priporočilo v zvezi s terapevtskim spremljanjem (za metotreksat, litij in ciklosporin).
The risk is believed to increase with dose and duration of therapy. 
Tveganje naj bi se povečevalo odvisno od odmerka in trajanja zdravljenja.
Solvent: One ampoule contains 2 ml water for injection 
Vehikel: Ena ampula vsebuje 2 ml vode za injekcije.
Studies not investigating the recommended doses of either 4 mg tid or 8 mg bid were excluded from the analysis. 
Raziskave, ki niso preučevale priporočenih odmerkov 4 mg trikrat dnevno ali 8 mg dvakrat dnevno, so bile izključene iz analize.
Recommended dose: 8 mg intravenous or intramuscular. 
Priporočeni odmerek: 8 mg intravensko ali intramuskularno.
Pharmacokinetic properties - Section 5.2 
Farmakokinetične lastnosti - poglavje 5.2
6.6 Special precautions for disposal and other handling The solution for injection is prepared by dissolving the content of one vial in water for injection from the accompanying ampoule, immediately prior to use. 
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Raztopino za injiciranje pripravimo neposredno pred uporabo z raztapljanjem vsebine ene viale v vodi za injekcije iz ampule, ki je priložena.
Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment. 
Bolniki z anamnezo toksičnosti za prebavila, zlasti starostniki, morajo sporočiti vse nenavadne abdominalne simptome (zlasti krvavitev v prebavilih), še posebej v začetnih fazah zdravljenja.
Maximum plasma concentrations are achieved after approximately 1-2 hours. 
Najvišje plazemske koncentracije doseže po približno 1-2 urah.
Therefore, the use of lornoxicam is contraindicated during the third trimester of pregnancy (see section 4.3). 
Zato je uporaba lornoksikama v tretjem tromesečju nosečnosti kontraindicirana (glejte poglavje 4.3).
4.5 Interaction with other medicinal products and other forms of interaction Concomitant administration of lornoxicam and - Cimetidine: Increased plasma concentrations of lornoxicam. 
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Sočasna uporaba lornoksikama in - Cimetidina: Zvišane plazemske koncentracije lornoksikama.
Gastrointestinal disorders 
Gastrointestinalni
The second meta-analysis included seven studies (CT01, CT02, CT03, CT14, CT32, CT78 and CT85) with orally applied lornoxicam including a total of 1581 patients. 
Druga metaanaliza je vključevala sedem raziskav (CT01, CT02, CT03, CT14, CT32, CT78 in CT85) s peroralno dajanim lornoksikamom s skupno 1581 bolniki.
Three of the lornoxicam patients participated in a study investigating the efficacy of lornoxicam in pain due to bone metastases in prostate cancer, which was the cause of death for two. 
Trije bolniki, zdravljeni z lornoksikamom, so sodelovali v raziskavi, ki je preučevala učinkovitost lornoksikama pri bolečinah zaradi kostnih metastaz pri raku prostate, zaradi česar sta umrla dva bolnika.
For all the pharmaceutical forms and strengths of lornoxicam It was agreed that the following contraindications would be included: - The third trimester of pregnancy (see section 4.6) 
Za vse farmacevtske oblike in jakosti lornoksikama Dogovorjeno je bilo, da se vključijo naslednje kontraindikacije: - Tretje trimesečje nosečnosti (glejte poglavje 4.6)
Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking). 
Podoben premislek je potreben pred začetkom dolgoročnega zdravljenja bolnikov z dejavniki tveganja za kardiovaskularne bolezni (npr. hipertenzija, hiperlipidemija, sladkorna bolezen, kajenje).
From clinical trial data there is no evidence of accumulation of lornoxicam after repeated administrations, when given according to recommended dosage. 
Podatki iz kliničnih preskusov ne kažejo akumulacije lornoksikama po ponovljenem dajanju priporočenih odmerkov.
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARIES OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 
DODATEK II ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA DOPOLNILO POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA, OZNAČEVANJA IN NAVODILA ZA UPORABO, KI JIH JE PREDSTAVILA EMEA
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES 
DODATEK I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE ZDRAVILA, IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
Maintenance dose should not exceed 16 mg lornoxicam daily. 
Vzdrževalni odmerek ne sme biti večji od 16 mg lornoksikama na dan.
injection use sufficiently long needle for a deep intramuscular injection. 
injekcijo morate uporabiti iglo, ki je dovolj dolga za globoko intramuskularno injiciranje.
- Quinolone antibiotics: Increased risk of seizures. 
- Kinolonski antibiotiki: Zvišano tveganje napadov.
Keep vial in the outer carton. 
Vialo shranjujte v zunanji škatli.
Although a considerable number of patients have been treated with lornoxicam so far, only few of the known serious reactions to other NSAIDs have been reported for lornoxicam. 
Čeprav je bilo z lornoksikamom zdravljenih že veliko bolnikov, so doslej pri lornoksikamu poročali o le nekaj znanih resnih učinkih NSAID.
- Known inducers and inhibitors of CYP2C9 isoenzymes: Lornoxicam (as other NSAIDs depending on the cytochrome P450 2C9 (CYP2C9 isoenzyme)) has interactions with known inducers and inhibitors of CYP2C9 isoenzymes (see section 5.2 Biotransformation). 
- Znani induktorji in zaviralci izoencimov CYP2C9: Lornoksikam (kakor ostala nesteroidna protivnetna zdravila, ki so odvisna od citokroma P450 2C9 (izoencim CYP2C9)) ima interakcije z znanimi induktorji in zaviralci izoencimov CYP2C9 (glejte poglavje 5.2 Biotransformacija).
Lornoxicam has shown compatibility with 0.9% NaCl, 5% dextrose (glucose) and Ringer's solution. 
Za zdravilo Lornoxicam je dokazana združljivost z raztopinama 0,9 % NaCl, 5 % dekstroze (glukoze) in Ringerjevo raztopino.
As outlined by the MAH this meta-analysis was restricted to placebo-controlled studies as the purpose of the analysis was to estimate a difference to placebo [Tab. 
Kot je navedel imetnik dovoljenja za promet, je bila metaanaliza omejena na s placebom kontrolirane raziskave, ker je bil namen analize ugotoviti razliko v primerjavi s placebom [Tabela 4].
Should any such abnormality prove significant or persist the administration of lornoxicam should be stopped and appropriate investigations prescribed. 
Če ugotovite, da so takšne nenormalnosti pomembne ali da ne izzvenijo, morate zdravljenje z lornoksikamom prekiniti in naročiti ustrezne preiskave.
The safety database (SDB) included all lornoxicam studies under the control of Nycomed Pharma (studies performed by third parties were excluded) comprised a total of 12,570 patients of who 7,427 received lornoxicam. 
Zbirka podatkov o varnosti, število bolnikov in izpostavljenost V zbirko podatkov o varnosti so bile vključene vse raziskave lornoksikama pod nadzorom družbe Nycomed Pharma (raziskave, ki so jih izvedle tretje strani, so bile izključene) s skupno 12.570 bolniki, od katerih jih je 7427 prejemalo lornoksikam.
Approximately 20% of patients treated with lornoxicam can be expected to experience adverse reactions. 
Neželene učinke lahko pričakujemo pri približno 20 % bolnikov, ki se zdravijo z lornoksikamom.
No data are available on simultaneous intake of Xefo Rapid film-coated tablets with meals, but based on data for Xefo film-coated tablets a reduction of Cmax, an increase in Tmax, and a reduction in the absorption (AUC) of lornoxicam may be expected. 
Ni razpoložljivih podatkov o sočasnem vnosu zdravila Xefo Rapid filmsko obložene tablete skupaj z obrokom, vendar podatki za zdravilo Xefo filmsko obložene tablete kažejo, da je pričakovati zmanjšanje Cmax, podaljšanje Tmax in zmanjšanje absorpcije (AUC) lornoksikama.
Eight patients died after lornoxicam treatment and three patients after treatment with comparators, and no case was reported after parenteral lornoxicam. 
Po zdravljenju z lornoksikamom je umrlo osem bolnikov, po zdravljenju s primerjalnimi zdravili trije bolniki, po parenteralni uporabi lornoksikama pa niso poročali o nobenem smrtnem primeru.
Eight placebo- and/or reference drug controlled clinical studies were performed in patients suffering from OA. 
Izvedenih je bilo osem s placebom in/ali referenčnim zdravilom kontroliranih kliničnih raziskav na bolnikih z osteoartritisom (OA).
Intravenous use Intramuscular use 
Intravenska uporaba Intramuskularna uporaba
Contraindications - Section 4.3 
Kontraindikacije - poglavje 4.3
Study CTX 87 was excluded since single doses of 4-20 mg LNX were administered i.m. 
Raziskava CTX 87 je bila izključena, ker so bili enkratni odmerki 4-20 mg lornoksikama dajani intramuskularno.
- Sulphonylureas: Increased risk of hypoglycaemia. 
- Sulfonilsečnina: Zvišano tveganje hipoglikemije.
Powder: Mannitol, Trometamol, Disodium edetate 
Prašek: manitol, trometamol, dinatrijev edetat
Special warnings and precautions for use - Section 4.4 
Posebna opozorila in previdnostni ukrepi - poglavje 4.4
All deaths reported for lornoxicam were considered unrelated to treatment by the responsible investigator and may reflect the multimorbid patients taking part in these studies. 
Noben smrtni primer, o katerem so poročali pri lornoksikamu, ni bil povezan z zdravljenjem, ki ga je izvajal odgovorni raziskovalec, kar lahko kaže na to, da so v teh raziskavah sodelovali bolniki z več boleznimi.
6.5 Nature and contents of container Aluminium/Aluminium blister. 
6.5 Vrsta ovojnine in vsebina Pretisni omot aluminij/aluminij.
0.9% sodium chloride solution 5% dextrose (glucose) solutions 
0,9-% raztopino natrijevega klorida 5-% raztopino dekstroze (glukoze)
Lornoxicam reduces platelet aggregation and prolongs bleeding time and consequently care should be taken when administering to patients with increased bleeding tendency. 
Zdravilo Lornoxicam zmanjša sposobnost agregacije trombocitov in podaljša čas krvavitve, zato je potrebna previdnost pri predpisovanju zdravila bolnikom, ki so bolj nagnjeni h krvavitvam.
the CHMP has recommended the amendment of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Xefo and associated names (see Annex I). 
je CHMP priporočil dopolnitev dovoljenj(a) za promet, za katere(ga) so Povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo podani v Dodatku III za zdravilo Xefo in z njim povezana imena (glejte Dodatek I).
There are no data on the excretion of lornoxicam in human breast milk. 
Ni podatkov o izločanju lornoksikama v materino mleko.
In rat, lornoxicam impaired fertility (effects on ovulation and implantation), and affected the pregnancy and delivery. 
Pri podganah je lornoksikam okvaril plodnost (vpliv na ovulacijo in nidacijo) in vplival na nosečnost ter skotitev.
For all the pharmaceutical forms and strengths of lornoxicam It was agreed that the following additional undesirable effects: weight changes, ecchymosis, prolonged bleeding time, bronchospasm, rhinitis, perforated peptic ulcer, pupura, increase in blood urea nitrogen and creatinine levels. 
Za vse farmacevtske oblike in jakosti lornoksikama Usklajeni so bili naslednji dodatni neželeni učinki: spremembe teže, ekhimoza, podaljšan čas krvavitve, bronhospazem, rinitis, perforirani peptični ulkus, purpura, povečanje koncentracije dušika sečnine in kreatinina v krvi.
Osteoarthritis and Rheumatoid arthritis 
Osteoartritis in revmatski artritis
The hydroxylated metabolite exhibits no pharmacological activity. 
Hidroksiliran presnovek ni farmakološko aktiven.
A plateau of efficacy was obtained with 8mg bid; this dosage regimen is thus considered the maximum dose for lornoxicam in RA. 
Plato učinkovitosti je bil dosežen z odmerkom 8 mg dvakrat dnevno; ta shema odmerjanja zato velja za največji odmerek lornoksikama pri RA.
Water for injection, 2 ml: Clear glass ampoule 
vodo za injekcije, 2 ml: ampula iz prozornega stekla.
In the literature, incidences of SADRs for NSAIDs vary between 0.3% and 4.7% indicating that the risk of developing SADRs with lornoxicam is similar to that of other NSAIDs. 
V literaturi se pogostost resnih neželenih učinkov zdravila pri NSAID giblje med 0,3 % in 4,7 %, kar kaže, da je tveganje za pojav resnih neželenih učinkov pri lornoksikamu podobno kot pri drugih NSAID.
The plasma protein binding of lornoxicam is 99 % and not concentration dependent. 
Vezava lornoksikama na plazemske beljakovine je 99 % in je neodvisna od koncentracije.